| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 06/03/2009 | EP1742628A4 Alternative forms of the phosphodiesterase-4 inhibitor n-cyclopropyl-1-{3-¬(1-oxidopryidin-3-yl)ethynyl phenyl}-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxyamide |
| 06/03/2009 | EP1480618B1 Sustained release drug formulations containing a carrier peptide |
| 06/03/2009 | EP1263720B1 Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same |
| 06/03/2009 | EP1218544B1 TAR RNA binding peptides |
| 06/03/2009 | CN101445486A Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone |
| 06/03/2009 | CN101444519A Therapeutic methods and delivery systems utilizing sex steroid precursors |
| 06/03/2009 | CN100494182C Regulatory factor of tumor necrosis alpha factor |
| 06/02/2009 | US7541378 tert-butyl 3-amino-1H-thieno[2,3-c]pyrazole-5-carboxylate; N-benzyl-3-[(4-fluorobenzoyl)amino]-1H-thieno[2,3-c]pyrazole-5-carboxamide; treats a disease caused associated with an altered (disregulated) protein kinase activity e.g cancer, cell proliferative disorders, Alzheimer's disease, viral infections |
| 06/02/2009 | US7541375 Azole derivatives and pharmaceutical compositions containing them |
| 06/02/2009 | US7541369 Amino-derivatives as novel inhibitors of histone deacetylase |
| 06/02/2009 | US7541362 7-(3,4-Dichlorophenyl)-4,7-dihydro-5-methyl-6-(5-phenyl-2-oxazolyl)pyrazolo[1, 5-a]pyrimidine |
| 06/02/2009 | US7541350 Formulation containing anti-inflammatory androstane derivative |
| 06/02/2009 | US7541337 Methods and compositions for the treatment of peripheral artery disease |
| 06/02/2009 | US7541018 Treatment process using somatostatin analogues |
| 06/02/2009 | CA2371728C High dose radionuclide complexes for bone marrow suppression |
| 06/02/2009 | CA2350425C Use of an insulin sensitiser for the treatment of type 2 diabetes mellitus |
| 06/02/2009 | CA2340416C Co-lyophilized complex of a nucleic acid vector and a formulating agent |
| 05/28/2009 | WO2009067268A1 Methods of enhancing diabetes resolution |
| 05/28/2009 | WO2009066712A1 Aromatase inhibitor |
| 05/28/2009 | WO2009066009A1 Novel 4,5-dihydroisoxazoles with estrogenic activity |
| 05/28/2009 | WO2009066008A1 Novel beta-hydroxyketones and beta-alkoxyketones with estrogenic activity |
| 05/28/2009 | WO2009065854A1 N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors |
| 05/28/2009 | WO2009065181A1 Nanostructures suitable for delivery of agents |
| 05/28/2009 | WO2009027482A3 Tsh receptor antagonizing tetrahydroquinoline compounds |
| 05/28/2009 | US20090137655 Non-Steroidal Ligands for the Glucocorticoid Receptor, Compositions and Uses Thereof |
| 05/28/2009 | US20090137604 corticotropin releasing factor receptor antagonists such as 8-(N-butyl-N-(2-butynyl)amino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine, used for the treatment of nervous system, psychological, eating, sleep, and gastrointestinal disorders |
| 05/28/2009 | US20090137536 Method for treating and preventing hyperparathyroidism |
| 05/28/2009 | US20090137478 Hormone normalization therapy and uses therefor |
| 05/28/2009 | US20090137040 Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
| 05/28/2009 | US20090136539 Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
| 05/28/2009 | US20090136527 Synthetic peptide comprising the amino acid sequence GPRLGYSWHX in which each of the amino acids are in the D-amino acid configuration and X is any amino acid; optionally conjugated to the natural gonadotropin-releasing hormone peptide; vaccines for use incontrolling fertility or heat in an animal |
| 05/28/2009 | US20090136419 parenterally administering a dose of samarium ethylenediaminetetramethylenephosphonic acid (EDTMP); and carboplatin or taxoids; anticarcinogenic, antitumor, and antantiproliferative agents; autoimmune, infectious , metabolic or genetic disorders |
| 05/28/2009 | CA2703893A1 Compound |
| 05/27/2009 | EP2062914A2 Somatostatin-dopamine chimeric analogs |
| 05/27/2009 | EP2062883A1 Insulin sensitivity improving agent |
| 05/27/2009 | EP2062879A1 Heterocyclic inhibitors of p38 |
| 05/27/2009 | EP1519915B1 Tricyclic steroid hormone nuclear receptor modulators |
| 05/27/2009 | EP1351672B1 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders |
| 05/27/2009 | EP1222174B1 Imidazol-4-ylmethanols used as inhibitors of steroid c17-20 lyase |
| 05/27/2009 | CN101443017A Medication against breast cancer and related diseases |
| 05/27/2009 | CN101443016A Use of 4, 17 beta-dihydroxyandrost-4-ene-3-one for treating cancers |
| 05/27/2009 | CN101443009A Antitumor agent for thyroid cancer |
| 05/27/2009 | CN101440343A Bitter melon health wine and preparation method thereof |
| 05/27/2009 | CN100491323C Biaryloxymethylarenecarboxylic acids compound |
| 05/27/2009 | CN100490797C Pharmaceutical compositions |
| 05/26/2009 | US7538125 Pioglitazone insulin sensitivity enhancer with the antidiabetic glimepiride; difference in mechanism of action avoids adverse reactions over long term use; oral dosage tablet; lactose excipient, hydroxypropylcellulose binder, magnesium stearate lubricant, calcium carbonate disintegrator; diabetes |
| 05/26/2009 | US7538118 6-aminomorphinane derivatives, method for production and use thereof |
| 05/26/2009 | US7538100 17α-alkyl-17β-oxy-estratrienes and intermediate products for their production, use of the 17α-alkyl-17β-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations |
| 05/26/2009 | US7538091 D-retro-inverso amino acid sequence transporter peptide conjugated to nucleic acid biological effector; translocation across the membrane of pancreatic B-cells |
| 05/26/2009 | US7537887 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds |
| 05/26/2009 | CA2497857C Novel p-selectin ligand protein |
| 05/26/2009 | CA2459432C Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders |
| 05/26/2009 | CA2454675C 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
| 05/26/2009 | CA2436668C Novel succinate salt of o-desmethyl-venlafaxine |
| 05/26/2009 | CA2387201C Tetrahydroquinoline derivatives |
| 05/26/2009 | CA2340701C Oxindole derivatives as growth hormone releasers |
| 05/26/2009 | CA2230492C Human growth hormone variants |
| 05/22/2009 | WO2009065126A2 Excipients for protein stabilization |
| 05/22/2009 | WO2009063993A1 Fused pyridine derivative and use thereof |
| 05/21/2009 | US20090131478 Growth Hormone Secretagogues |
| 05/21/2009 | US20090131456 Caspase inhibitors and uses thereof |
| 05/21/2009 | US20090131404 Combinations |
| 05/21/2009 | US20090130681 21132, a Human G-protein coupled receptor family member and uses therefor |
| 05/21/2009 | US20090130080 Reducing blood glucose level in a non-obese or obese human afflicted with Type 2 diabetes by administering purified human placental alkaline phosphatase |
| 05/21/2009 | US20090126732 Dry powder inhalation system for transpulmonary administration |
| 05/20/2009 | EP2060268A1 Pharmaceutical compositions for pulmonary or nasal delivery of peptides |
| 05/20/2009 | EP2059802A2 Methods for designing parp inhibitors and uses thereof |
| 05/20/2009 | EP2059260A2 Pharmaceutical compositions comprising hgh for oral delivery |
| 05/20/2009 | EP1365760B1 Preparations and use of an ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester |
| 05/20/2009 | EP1208113B1 17beta-acyl-alpha-propynyl-11beta-(cyclic amino)aryl steroids and their derivatives having antagonist hormonal properties |
| 05/20/2009 | CN101433598A Uses of giant knotweed for preventing and treating insulin resistance and related metabolic diseases thereof |
| 05/20/2009 | CN100488566C Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant |
| 05/20/2009 | CN100488560C Method for preparing mass micro-capsule |
| 05/19/2009 | US7534863 Leucine-based motifs and enhanced biological persistence of clostridial neurotoxins |
| 05/19/2009 | US7534802 Compounds having 4-pyridylalkylthio group as substituent |
| 05/19/2009 | US7534773 reduces the expression of testosterone-repressed prostate message-2 provides therapeutic benefits in the treatment of cancer for example prostate cancer and renal cell cancer; Combined use with taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer |
| 05/19/2009 | US7534427 Predosing with non-radiolabeled antibody not performed |
| 05/19/2009 | CA2382580C Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders |
| 05/19/2009 | CA2312004C Site-specific preparation of polyethylene glycol-grf conjugates |
| 05/14/2009 | WO2009062082A2 Selective estrogen receptor modulator compositions and methods for treatment of disease |
| 05/14/2009 | WO2009025792A3 Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof |
| 05/14/2009 | US20090124547 conjugated drug comprising nerve growth factor linked to a steroid; for tissue-targeted therapy; treating pain |
| 05/14/2009 | US20090124544 Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| 05/14/2009 | US20090123534 comprising progesterone, soy bean lecithin, and olive oil, wherein at least about 80% of the particles of progesterone are characterized by a particle size of between 1 and 15 mu m; for treating a physiological condition linked to insufficiency of progesterone secretion |
| 05/14/2009 | US20090123530 Liposome Drug Delivery |
| 05/14/2009 | DE102007044066A1 Use of polysaccharide from fruit of Lycium barbarum to produce a medicament, nutritional supplement or food for the prevention against and for therapy of diseases, preferably nephropathy and disorders of organs in retroperitoneal cavity |
| 05/14/2009 | CA2714808A1 Selective estrogen receptor modulator compositions and methods for treatment of disease |
| 05/13/2009 | EP2058309A1 Fused heterocyclic compound |
| 05/13/2009 | EP1655028B1 Use of cyclic bioisosteres of purine system derivatives for the treatment of diseases caused by disorders of nitrergic and dopaminergic systems |
| 05/13/2009 | CN101428054A Uses of rhodiola rosea in preventing and treating insulin resistance, and correlated metabolism diseases |
| 05/13/2009 | CN100486583C Diabetin for injection and its preparation process |
| 05/13/2009 | CN100486570C Use of luciferin and derivatives in preparing medicine for treating live animal secretory diarrhea and inhibiting cyst growth |
| 05/12/2009 | US7531635 Monoclonal antibodies or functional fragment; immunoassay kit; female fertility diagnosis; Premature ovarian failure |
| 05/12/2009 | US7531571 4-benzyl-2-phenylchroman skeleton with hydroxyl substitutions compounds; estrogen beta -receptors (ER beta ) modulator; hormone replacement therapy; osteoporosis, postmenopause; side effect reduction |
| 05/12/2009 | US7531564 Substituted benzoxazoles as estrogenic agents |
| 05/12/2009 | US7531536 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease |
| 05/12/2009 | US7531528 mixture of aqueous carrier liquid containing dissolved glucocorticoid and 3-oxoandrostane carbothioic coompound |
| 05/12/2009 | US7531304 Method for screening FGFR-4 agonists |
| 05/12/2009 | CA2589989C The use of the neurotoxic component of a botulinum toxin for the treatment of exessive sweating |
| 05/07/2009 | WO2009057622A1 Method for production of human growth hormone improved in efficiency |